SCHEMBL1643183

SCHEMBL1643183

COC(=O)Cc1ccc(OC)c(Oc2ccc(C(F)(F)F)cc2C=O)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PTGDR2 Q9Y5Y4 4/20 0.42
KMT2A Q03164 2/20 0.41
TBXA2R P21731 2/20 0.41
PTGDR Q13258 2/20 0.41
HTT P42858 1/20 0.40
MMP1 P03956 1/20 0.40
CSNK1D P48730 1/20 0.40
PPARD Q03181 2/20 0.39
PPARA Q07869 2/20 0.39
ABL1 P00519 1/20 0.39
RIN1 Q13671 1/20 0.39
MAPT P10636 1/20 0.39
SCN8A Q9UQD0 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643068 0.90 MMP1 (0.41) KDM4ETDP1LMNASMN1; SMN2PTGDR2
SCHEMBL137376 0.84 PTGDR2 (0.53) PTGDR2TBXA2RPTGDR
SCHEMBL1011232 0.83 CSNK1D (0.45) KDM4ELMNAKMT2AHTTCSNK1D
SCHEMBL1643019 0.83 LMNA (0.47) KDM4ETDP1LMNASMN1; SMN2PTGDR2
SCHEMBL1008948 0.83 KDM4E (0.47) KDM4ELMNASMN1; SMN2PTGDR2HTT
SCHEMBL13580745 0.83 MAPT (0.41) KDM4ELMNASMN1; SMN2KMT2AHTT
SCHEMBL13760999 0.82 PTGDR2 (0.46) KDM4ETDP1LMNASMN1; SMN2PTGDR2
SCHEMBL1644488 0.82 PTGDR2 (0.46) KDM4ETDP1LMNASMN1; SMN2PTGDR2
SCHEMBL14715822 0.79 TTR (0.49) LMNASMN1; SMN2KMT2AHTTMAPT
SCHEMBL6407212 0.79 ALDH1A1 (0.49) KDM4ETDP1LMNAKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-8242145-B2 Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-14 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
WO-2009102893-A2 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors AMIRA PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098302-A1 CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER1 KDM4E 4391/4885TDP1 4507/4885LMNA 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.